FAQs AGA

It depends on each case: age, concomitant diseases, and genetic factors... as Androgenetic Alopecia (AGA) is a multifactorial condition. Microscopically, a significant reduction in the number of miniaturized hairs can be observed within three months. By the fourth month, changes in the quality and number of hairs are visible to the naked eye, as well as a high hair density. It is important to stress the importance of diagnosing AGA as the cause of hair loss for the protocol to be effective.

The procedure has been used for more than 4 years and the long-term results are exceptional, since it slows down the evolution of AGA in a biological way, although that does not mean that it cannot be complementary to other treatments to have better hair quality.  

Poor results can be observed when androgenetic alopecia courses with very few miniaturized hairs or when the onset or progression of the signs is extremely fast. We may also obtain scarce results when treating a scalp undergoing an inflammation process or with concomitant pathologies such as effluviums. For this reason, diagnosis is essential 

The diagnosis is essential, as indicated by the protocol. AMT® has only proved efficacy on the AGA kind of alopecia. For this reason, it is important to know whether your patient’s AGA is accompanied by another pathology such as telogen effluvium, an inflamed scalp or another pathology, since it can fully affect the success of the procedure. It is relevant not to have advanced evolutionary alopecia, as well as a normal blood test.

It is under these conditions that the AMT® can help to slow down the evolution of androgenetic alopecia in a biological way.

The procedure has no complications if performed under sterile conditions and strictly complies with the protocol, since it is an autologous (tissue from the same patient) and homologous (tissue from the same embryonical origin) micrografting procedure. AMT® stands out for being a minimally invasive and fast procedure that takes no more than 30 minutes to perform. 

One of the main advantages of the AMT® procedure is its low invasiveness, which allows a quick recovery in about 24-48 hours, during which the patient is not allowed to wet the donor area. 

The AMT® procedure is a highly quick intervention, lasting about 20-25 minutes each and results can last over 3 years. 

With the AMT® procedure doctors obtain a micrograft solution that comes from skin biopsies that have the same embryological origin as the receptor site (homologous), meaning that the pathways activated with this procedure are much more specific than in a PRP treatment. Moreover, unlike PRP, the AMT® procedure generates a solution which contains not only growth factors, but also progenitor cells that remain in the patient’s scalp. Those cells will be continuously delivering cytokines, chemokines and growth factors to enhance regenerative properties of the affected area, for years. As a result, the healing will be much more efficient, and the results will be better and last longer.   

The procedure with AMT® Protocol on AGA consists of a seeding of complete grafts of follicular units; meaning, for example, that the first capillary line can be advanced only if there are hair follicles with small diameter and density. It is important to note that AMT® Protocol has the potential to "nourish" the damaged area, since micro-grafts provide biological/molecular tools so that the cells themselves within the affected area can regenerate tissue and save hair follicles from miniaturization.  

Yes, indeed, its inflammation-modulating and neovascularisation-generating action makes it easier for the hair graft to survive, for the same reason it can rescue follicles in regression. Moreover, the antioxidant properties of the AMT® Solution help in the survival of extracted grafts during a hair transplant procedure, while helping the healing process of the donor site.  

By injecting the micro-grafts in the affected area these cells are able to perceive the microenvironment that surrounds them. Bernardo et al 2013 demonstrates that progenitor cells in vivo are sensors of inflammation and can adopt a pro-inflammatory or anti-inflammatory phenotype by interfering with innate and adaptive immune responses.  

In addition, Penn et al 2009 and Aggarwal et al 2006 have demonstrated that in vivo progenitor cells secrete massive levels of bioactive agents such as growth factors, cytokines and chemokines, which are immunomodulatory and trophic factors.  

To understand the therapeutic potential of micro-grafts, it is crucial to understand that the role of progenitor cells is to modify the tissue homeostasis where they are included, as well as inflammation. This causes a substantial increase in the regenerative capacity of the progenitor cells of the tissue.  

AMT® can be useful in all stages of an AGA process in different ways. In an initial stage, it can be used as a preventive immunotherapy procedure thanks to the numerous cytokines, chemokines and growth factors that will nourish hair follicles. In mild-moderate stages, it can be useful in combination with other therapies to help rescuing hair follicles in severe states of miniaturization. In advanced stages of AGA, it can be used in combination with a hair transplant, to both accelerate healing and enhance the success rate of transplanted UFCs. 

Being AMT® procedure on AGA Management an autologous and homologous procedure, it can be combined with any therapy, without any risks of cross-over reaction, since the whole process is done with cells from the own patient and saline solution, with no extra chemicals added. 

If you cannot find the answer to your question here, you can get in touch with us through the Contact form.